UNQUOTE

SWITZERLAND - 4-Antibody raises CHF 17m series-A financing round

  • Wietske Blees
  • LinkedIn  
  • Google plus  

4-Antibody AG has received a CHF 17m series-A financing round led by new investor Advent Venture Partners, together with existing lead investors Life Sciences Partners (LSP) and BioMedinvest AG. All other existing investors Grazia Equity, Mulligan Biocapital and several private investors also participated. LSP led a seed round in 2004. The total financing has been brought to CHF 23m ($18.5m).

4-Antibody AG is s biopharmaceutical company focused on the improvement of existing antibodies and the discovery of de-novo fully human antibodies. The proceeds will be used to accelerate the discovery and development of novel therapeutic monoclonal antibodies. The company is based in Basel and operates a wholly owned subsidiary in Jena, Germany.
  • LinkedIn  
  • Google plus  

More on Expansion

Latest News